

A Randomized Phase III Trial of Intravesical BCG Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG Naive High Grade Non-Muscle Invasive Bladder Cancer (BRIDGE)

Status: Recruiting

Eligibility Criteria

Sex: Male or Female

Age Group: 18 years and over

This study is NOT accepting healthy volunteers

Inclusion Criteria:

- at least 18 years old - diagnosis of confirmed high-grade non-muscle invasive urothelial carcinoma of the bladder - have not received prior intravesical therapy for bladder cancer - capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours - see link to clinicaltrials.gov for complete inclusion and exclusion criteria

Exclusion Criteria:

- must not have any prior or current history of muscle-invasive, locally advanced unresectable, or metastatic urothelial cancer - women who are pregnant or breast feeding

Conditions & Interventions

Interventions:

Drug: Bacillus Calmette Guerin, Drug: Docetaxel, Drug: Gemcitabine

Conditions:

Cancer

Keywords:

bladder cancer, Clinics and Surgery Center (CSC), urothelial Cancer

More Information

Description: We want to see if we can lower the chance of bladder cancer growing or spreading by using a type of chemotherapy instilled in the bladder, Gemcitabine and Docetaxel. The usual approach for patients who are not in a study is treatment with Transurethral surgery of bladder tumor (TURBT) followed by instillations of Bacillus Calmette-Guerin (BCG) immunotherapy into the bladder via a catheter.

Study Contact: Mary Jo Hadler - hadle010@umn.edu

Principal Investigator: Hamed Ahmadi

Phase: PHASE3

IRB

Number: STUDY00021094

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.